Skip to main content

Table 1 No correlations of epigenetic aging acceleration estimated by three clocks with the psychosis symptom severity and symptom improvement in patients with drug-naive first-episode SCZ

From: Epigenetic clock analysis of blood samples in drug-naive first-episode schizophrenia patients

Valuable

Horvath’s AgeAccel

Hannum’s AgeAccel

Levine’s PhenoAgeAccel

β

P value

β

P value

β

P value

Baseline PANSS Scores

 Positive syndromes

−0.02

0.92

0.22

0.23

0.35

0.06

 Negative syndromes

−0.03

0.88

0.07

0.69

0.17

0.31

 General syndromes

−0.05

0.78

0.07

0.70

0.13

0.47

 PANSS total syndromes

−0.05

0.79

0.14

0.42

0.27

0.13

Percentage change in PANSS Scores

 Percentage change in positive syndromes

−0.02

0.92

0.04

0.80

−0.25

0.15

 Percentage change in negative syndromes

0.05

0.78

−0.22

0.18

−0.34

0.05

 Percentage change in general syndromes

0.07

0.69

0.10

0.56

−0.03

0.85

 Percentage change in PANSS total syndromes

0.07

0.67

0.02

0.89

−0.23

0.19

  1. Multiple linear regression analyses were conducted to assess the relationship of baseline epigenetic age acceleration with baseline psychosis symptom severity and symptom improvement after 8-week treatment in SCZ patients adjusting for age, sex, tobacco use, and illness duration